Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

This article was co-authored with Emma Myer, a student at Washington and Lee University who studies Cognitive/Behavioral Science and Strategic Communication. In today’s digital age, social media has ...

“Algospeak” capitalizes on our desire for attention and status. We should turn to God for both. I’ll typically start formulating ideas around 7 a.m. Thanks to a steady stream of information from my ...

Speaking at WSJ Opinion Live in Washington, D.C., WSJ Editorial Page Editor Paul Gigot and SandboxAQ CEO Jack Hidary discuss Large Quantitative Models (LQMs) and their role in AI applications, the ...

With autism prevalence now reaching 1 in 31 children in the United States according to the latest CDC data, the pressure on ABA practices to support timely, accurate diagnosis has never been greater.

This is read by an automated voice. Please report any issues or inconsistencies here. We are more connected than ever before, with our high-speed internet, pinging smartphones and ever-updating apps ...

Jackie Allen, Jr., a third-generation farmer in Bardstown, Kentucky, leases two hundred and sixty acres near the Beech Fork River, and accepts that the family business ends with him. His progeny ...

Forbes contributors publish independent expert analyses and insights. Vibhas Ratanjee studies leadership and culture at Gallup This voice experience is generated by AI. Learn more. This voice ...

The workplace can be a tricky place to navigate. Almost everything we do at work—identifying the experts, managing tough feedback from a boss, figuring out how to work in teams made up of different ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...